Global Human Insulin Market

1 INTRODUCTION OF GLOBAL HUMAN INSULINMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HUMAN INSULINMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL HUMAN INSULIN MARKET, BY APPLICATION:
5.1 Type I Diabetes
5.2 Type II Diabetes

6 GLOBAL HUMAN INSULIN MARKET, BY DELIVERY DEVICES:
6.1 Syringes
6.2 Pens
6.2.1 Disposable Pens
6.2.2 Reusable Pens
6.3 Pen Needles
6.3.1 Standard Pen Needles
6.3.2 Safety Pen Needles

7 GLOBAL HUMAN INSULIN MARKET, BY BRAND:
7.1 HI Analogs and Biosimilars
7.1.1 Lantus
7.1.2 Novorapid and Novolog
7.1.3 Humalog
7.1.4 Other Brands
7.2 HI Biologics
7.2.1 Actrapid, Mixtard, and Insulatard
7.2.2 Humulin
7.2.3 Insuman

8 GLOBAL HUMAN INSULIN MARKET, BY TYPE:
8.1 Insulin Analogs and Biosimilars
8.1.1 Long-Acting Biosimilars
8.1.2 Rapid-Acting Biosimilars
8.1.3 Premixed Biosimilars
8.2 HI Biologics
8.2.1 Short-Acting Biologics
8.2.2 Intermediate-Acting Biologics
8.2.3 Premixed Biologics

9 GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE:
9.1 HI Drugs
9.2 HI Delivery Devices

10 GLOBAL HUMAN INSULINMARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

11 GLOBAL HUMAN INSULINMARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies

12 COMPANY PROFILES
12.1 B. Braun Melsungen AG
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments

12.2 Becton, Dickinson and Company
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments

12.3 Biocon Limited
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments

12.4 Biodel Inc.
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments

12.5 ELI Lilly and Company
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments

12.6 Julphar (Also Known as Gulf Pharmaceutical Industries)
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments

12.7 NOVO Nordisk A/S
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments

12.8 Sanofi
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments

12.9 Wockhardt Limited
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Development

12.10 Ypsomed AG
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Development

13 Appendix
13.1 Related Reports